HomeCompareOCTHF vs DGRO

OCTHF vs DGRO: Dividend Comparison 2026

OCTHF yields 71428.57% · DGRO yields 2.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OCTHF wins by $1.6804617092236922e+25M in total portfolio value
10 years
OCTHF
OCTHF
● Live price
71428.57%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.6804617092236922e+25M
Annual income
$16,758,464,082,723,930,000,000,000,000,000.00
Full OCTHF calculator →
DGRO
iShares Core Dividend Growth ETF
● Live price
2.10%
Share price
$70.18
Annual div
$1.47
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.6K
Annual income
$235.38
Full DGRO calculator →

Portfolio growth — OCTHF vs DGRO

📍 OCTHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCTHFDGRO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCTHF + DGRO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCTHF pays
DGRO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCTHF
Annual income on $10K today (after 15% tax)
$6,071,428.57/yr
After 10yr DRIP, annual income (after tax)
$14,244,694,470,315,339,000,000,000,000,000.00/yr
DGRO
Annual income on $10K today (after 15% tax)
$178.14/yr
After 10yr DRIP, annual income (after tax)
$200.07/yr
At 15% tax rate, OCTHF beats the other by $14,244,694,470,315,339,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCTHF + DGRO for your $10,000?

OCTHF: 50%DGRO: 50%
100% DGRO50/50100% OCTHF
Portfolio after 10yr
$8.402308546118461e+24M
Annual income
$8,379,232,041,361,964,000,000,000,000,000.00/yr
Blended yield
99.73%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCTHF buys
0
DGRO buys
0
No recent congressional trades found for OCTHF or DGRO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCTHFDGRO
Forward yield71428.57%2.10%
Annual dividend / share$2.00$1.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$1.6804617092236922e+25M$31.6K
Annual income after 10y$16,758,464,082,723,930,000,000,000,000,000.00$235.38
Total dividends collected$1.6801590475897682e+25M$2.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: OCTHF vs DGRO ($10,000, DRIP)

YearOCTHF PortfolioOCTHF Income/yrDGRO PortfolioDGRO Income/yrGap
1← crossover$7,153,557$7,142,857.14$11,290$209.57+$7.14MOCTHF
2$4,783,059,608$4,775,405,302.31$12,722$213.54+$4783.05MOCTHF
3$2,989,196,089,253$2,984,078,215,471.53$14,314$217.18+$2989196.07MOCTHF
4$1,746,108,740,720,723$1,742,910,300,905,223.00$16,080$220.53+$1746108740.70MOCTHF
5$953,366,906,359,837,700$951,498,570,007,266,600.00$18,040$223.59+$953366906359.82MOCTHF
6$486,546,837,026,708,500,000$485,526,734,436,903,500,000.00$20,215$226.40+$486546837026708.50MOCTHF
7$232,096,820,383,666,640,000,000$231,576,215,268,048,070,000,000.00$22,627$228.96+$232096820383666624.00MOCTHF
8$103,489,940,016,498,150,000,000,000$103,241,596,418,687,620,000,000,000.00$25,302$231.31+$103489940016498147328.00MOCTHF
9$43,133,653,750,454,530,000,000,000,000$43,022,919,514,636,880,000,000,000,000.00$28,268$233.44+$4.313365375045453e+22MOCTHF
10$16,804,617,092,236,920,000,000,000,000,000$16,758,464,082,723,930,000,000,000,000,000.00$31,557$235.38+$1.6804617092236922e+25MOCTHF

OCTHF vs DGRO: Complete Analysis 2026

OCTHFStock

Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 receptor agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.

Full OCTHF Calculator →

DGROETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →
📬

Get this OCTHF vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCTHF vs SCHDOCTHF vs JEPIOCTHF vs OOCTHF vs KOOCTHF vs MAINOCTHF vs VIGOCTHF vs NOBLOCTHF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.